阿摩線上測驗
73. 依據 2023 AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma，下列何者敘述正確？
(1) Patients with advanced HCC who have Child-Turcotte-Pugh A cirrhosis
should be offered atezolizumab plus bevacizumab or durvalumab plus
tremelimumab as preferred first-line therapy options
(2) Patients with recent GI bleeding within 6 months and those with high-risk
stigmata for bleeding on EGD should have varices adequately treated prior
to atezolizumab plus bevacizumab initiation, or these patients may be
considered for durvalumab plus tremelimumab
(3) AASLD advises sorafenib or lenvatinib as preferred agents after first-line
durvalumab plus tremelimumab if patients are not eligible for clinical trials
(4) Well-selected patients with Child-Turcotte-Pugh B cirrhosis may be offered
sorafenib, lenvatinib, or single-agent anti-PD1 or anti-PDL1 ICI therapy
(A) (3)＋(4)
(B) (1)＋(2)＋(4)
(C) (3)
(D) (1)＋(2)＋(3)
(E) (1)＋(2)＋(3)＋(4)
(1) Patients with advanced HCC who have Child-Turcotte-Pugh A cirrhosis
should be offered atezolizumab plus bevacizumab or durvalumab plus
tremelimumab as preferred first-line therapy options
(2) Patients with recent GI bleeding within 6 months and those with high-risk
stigmata for bleeding on EGD should have varices adequately treated prior
to atezolizumab plus bevacizumab initiation, or these patients may be
considered for durvalumab plus tremelimumab
(3) AASLD advises sorafenib or lenvatinib as preferred agents after first-line
durvalumab plus tremelimumab if patients are not eligible for clinical trials
(4) Well-selected patients with Child-Turcotte-Pugh B cirrhosis may be offered
sorafenib, lenvatinib, or single-agent anti-PD1 or anti-PDL1 ICI therapy
(A) (3)＋(4)
(B) (1)＋(2)＋(4)
(C) (3)
(D) (1)＋(2)＋(3)
(E) (1)＋(2)＋(3)＋(4)
答案：登入後查看
統計： A(0), B(0), C(0), D(0), E(3) #3588529
統計： A(0), B(0), C(0), D(0), E(3) #3588529
